Podcasts about MSI

Is this GenG the best League of Legends team of all time? Thorin and Yamato react to the latest results from First Stand, assess GenG's quick win over JDG, analyze G2 and their chances of getting wins against LPL and LCK teams, share predictions for upcoming matches, discuss a comment made by T1 Oner about MSI, and more!   Sign up for your one-dollar-per-month trial today at https://shopify.com/summoning   Raycon's Essential Open Earbuds are perfect for refreshing your routine this spring! Go to https://buyraycon.com/LFNOPEN to get 20% off.   Head to https://factormeals.com/lfn50off and use code lfn50off to get 50 percent off and free breakfast for a year!   Livetrade on LoL today on Polymarket: https://polymarket.com/?via=lastfreenation-eeux Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Iran conflict continues to escalate, and the messaging coming out of the White House is raising more questions than answers. In a new interview with Brian Kilmeade, Donald Trump delivered a string of eyebrow-raising remarks, including comments about immigrants having “bad genetics” and suggesting he'll know the war is over when he simply “feels it in his bones.” Meanwhile, the consequences of the conflict are already being felt at home. Energy markets are reacting, prices are creeping up, and Americans are being told this war is necessary even as the administration struggles to explain what the actual endgame is. Tonight, Don breaks down the latest developments in the Iran conflict, the increasingly bizarre rhetoric coming from Trump, and the growing concern that this war has no clear plan and no clear end.

On this episode of The Dive Driven by Kia we're graced with a special guest; Commissioner MarkZ stopped by to chat about Spring Split details and help our hosts find the silver lining after Americas Cup. While NA teams didn't have their best showing, there were important learnings and stress tests leading up to First Stand and MSI. There's always a rebound angle, right?And speaking of First Stand, the tournament kicks off next week! We're looking to our leading Lyons to bring us to victory, though there's definitely some TOUGH competition ahead of us from the other regions (looking at you, GenG!) Get ready for 6 straight days of double best-of-5s- more League of Legends than you could even dream of!Finally, though there will be no new episodes of The Dive until April… you CAN keep up with our hosts as they may or may not taking over the @LCSOfficial socials to bring you content straight from Brazil during First Stand! We'll see you there.Timestamps:0:00 - INTRO & Welcome to Mark!1:06 - Americas Cup Review10:01 - Americas Cup Takeaways19:53 - Spring Split Primer23:38 - First Stand Preview25:06 - Lyon vs Loud35:48 - GenG vs JDG43:48 - BNK vs BLG56:44 - G2 vs TSW1:09:27 - Life Updates!

New reporting and deposition footage have raised serious questions about the people from DOGE, including staffers who reportedly had access to sensitive government data like Social Security information, and one particularly painful deposition where a staffer pushing anti-DEI policies struggled to even explain what DEI actually stands for. All this from the same crowd that was aggressively pushing efforts to strip references to Black history, women's history, and diversity initiatives from public institutions. So this morning Don breaks down the latest revelations, the uncomfortable depositions, and the bigger question: who exactly was put in charge of the country's data and institutions… and did they have any idea what they were doing?

The fallout from Trump's escalating conflict with Iran is growing, and the political backlash is getting louder. Polls show the war is deeply unpopular with Americans, with majorities disapproving of the strikes and questioning the administration's strategy. Even some prominent voices on the right are pushing back, warning that the conflict contradicts the “America First” promise to avoid new foreign wars. Meanwhile, a growing chorus online is asking whether this sudden military escalation is also serving as a distraction from the ongoing controversies surrounding Jeffrey Epstein and the unanswered questions many Americans still have. This episode is sponsored by MSI. Donate today Text LEMON to 511511, or https://MSIUnitedStates.org This episode is brought to you by BiOptimizers. Go to https://bioptimizers.com/donlemon and use my exclusive code DON15 to get 15% off any order. Make 2026 the year you finally start sleeping great again. This episode is sponsored by Graza. Take your food to the next level with Graza. Visit https://graza.co/LEMON and use promo code LEMON today for 20% off your first order! This episode is brought to you by Shopify. See less carts go abandoned and more sales go with Shopify and their Shop Pay button.Sign up for your one-dollar-per-month trial today at https://SHOPIFY.COM/lemon For free and unbiased Medicare help, dial 212-931-0855 to speak with my trusted partner, Chapter, or go to https://askchapter.org/don DISCLAIMER: Chapter and its affiliates are not connected with or endorsed by any government entity or the federal Medicare program. Chapter Advisory, LLC represents Medicare Advantage HMO, PPO, and PFFS organizations and stand alone prescription drug plans that have a Medicare contract. Enrollment depends on the plan's contract renewal. While we have a database of every Medicare plan nationwide and can help you to search among all plans, we have contracts with many but not all plans. As a result, we do not offer every plan available in your area. Currently we represent 50 organizations which offer 18,160 products nationwide. We search and recommend all plans, even those we don't directly offer. You can contact a licensed Chapter agent to find out the number of products available in your specific area. Please contact Medicare.gov, 1-800-Medicare, or your local State Health Insurance Program (SHIP) to get information on all of your options. Average potential savings are based on realized premium, co-pay, and out of pocket savings estimates self-reported by consumers that worked with Chapter Advisory LLC to enroll in a Medicare Supplement, Medicare Advantage, and/or Part D Prescription Drug Plan. The average is limited to consumers that chose to self-report. Savings information is subject to periodic updates and corrections. There is no guarantee of savings and any savings may vary by policy type, state, or other factors. Learn more about your ad choices. Visit megaphone.fm/adchoices

This morning, Don breaks down the latest updates from the escalating Iran conflict, the wildly inconsistent messaging coming out of the White House and the Pentagon, and what it means for the U.S., the Middle East, and the rest of the world. One minute they say the conflict could be over “very soon,” and then next it's “just the beginning.” Meanwhile, the official justification for the war seems to change depending on the day, from stopping nuclear weapons to regime change to protecting shipping lanes. Are we looking at a short-term military operation, or the start of another endless war? And why does it feel like the people running this thing are making it up as they go along? This episode is brought to you by Shopify. See less carts go abandoned and more sales go with Shopify and their Shop Pay button.Sign up for your one-dollar-per-month trial today at https://SHOPIFY.COM/lemon This episode is sponsored by MSI. Donate today Text LEMON to 511511, or https://MSIUnitedStates.org This episode is brought to you by BiOptimizers. Go to https://bioptimizers.com/donlemon and use my exclusive code DON15 to get 15% off any order. Make 2026 the year you finally start sleeping great again. This episode is sponsored by Graza. Take your food to the next level with Graza. Visit https://graza.co/LEMON and use promo code LEMON today for 20% off your first order! WE HAVE MERCH!! Purchase here: https://don-lemon-merch-store.myshopify.com/ WATCH & Subscribe on YouTube @TheDonLemonShow! Become a member of our channel here: https://www.youtube.com/channel/UCXs0PlIGUDSXfBaF7j-1euA/join Follow Don on Substack! Listen on Apple, Spotify and iHeart Radio! Learn more about your ad choices. Visit megaphone.fm/adchoices

Tonight we're diving into the growing rift inside the MAGA world as prominent right-wing voices and some of Trump's own supporters question the escalating conflict in the Middle East. Even figures who normally defend Trump are pushing back, arguing this war looks a lot like the very foreign entanglements he once promised to avoid. Meanwhile, the geopolitical situation is spiraling with regional retaliation, soaring oil prices, and fears of a wider war across the Middle East. And here at home? Polls show a majority of Americans disapprove of how Trump is handling the Iran conflict. So… is the MAGA coalition starting to crack? And how will this play with voters while Trump's approval numbers continue to drop? This episode is sponsored by Graza. Take your food to the next level with Graza. Visit https://graza.co/LEMON and use promo code LEMON today for 20% off your first order! This episode is brought to you by Shopify. See less carts go abandoned and more sales go with Shopify and their Shop Pay button.Sign up for your one-dollar-per-month trial today at https://SHOPIFY.COM/lemon This episode is sponsored by MSI. Donate today Text LEMON to 511511, or https://MSIUnitedStates.org This episode is brought to you by BiOptimizers. Go to https://bioptimizers.com/donlemon and use my exclusive code DON15 to get 15% off any order. Make 2026 the year you finally start sleeping great again. Learn more about your ad choices. Visit megaphone.fm/adchoices

Don't Put All Your Eggs In One Basket! Supersize You Annual Challenge Day 68! Join us every day in 2026 for a quick challenge that is all about you Improving and creating the life you want! https://www.facebook.com/ThrivingSharon Ask your questions and share your wisdom! #supersizeannualchallenge #doonethingeverydaytosupersizeyou #annualchallenge #confidence #supersizeyouannualchallenge #supersizeyouchallenge #financialwellbeing #financialhealth #dontputallyoureggsinonebasket #multiplestreamsofincome #MSI #waystomakemoney #passiveincome #diversify Hey there! Sharon Horne-Ellstrom here, discussing the importance of having multiple streams of income

MSI Reproductive Choices Presented by Deborah Frances-White and Grace Campbell with special guest Sarah Shaw Recorded 2 March 2026 via Riverside. Released 8 March. The Guilty Feminist theme composed by Mark Hodge. Donate today to MSI Reproductive Choices https://www.msichoices.org/guiltyfeminist/ Instagram explainer on the Global Gag Rule https://www.instagram.com/p/DUIJpGLjCe1/?img_index=1 More details on the Global Gag Rule on the MSI website https://www.msichoices.org/latest/explained-the-us-global-gag-rule/ For more information about this and other Guilty Feminist episodes… visit https://www.guiltyfeminist.com tweet us https://www.twitter.com/guiltfempod like our Facebook page https://www.facebook.com/guiltyfeminist check out our Instagram https://www.instagram.com/theguiltyfeminist or join our mailing list http://www.eepurl.com/bRfSPT Come to a live show 31 March Bloomsbury Theatre. https://www.bloomsburytheatre.com/event/2026/03/guilty-feminist-live 30 April, Guilty Feminist x The Nerve. https://www.leicestersquaretheatre.com/show/guilty-feminist-x-the-nerve-road-to-gilead 10 April, 17 April, 14 May, 22 May Museum of Comedy. https://www.museumofcomedy.com/the-guilty-feminist The Guilty Feminist is part of the AudioPlus Network. If you'd like to work with us, please get in touch at hello@weareaudioplus.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kebaktian 1 Minggu Prapaskah KetigaGKP Jemaat BandungMinggu, 8 Maret 2026 pukul 07.00 WIB Tema : Nigeria - "Aku Akan Memberikan Kelegaan Kepadamu Datanglah"Bacaan Alkitab : Matius 11:28-30Pelayan Firman : Pdt. Fierdhaus Y. Nyman, MSi.@GKP Bandung Maret 2026

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Drie heren zitten klaar in de studio van Gamekings om jouw weekend even goed in te luiden. We hebben het over Huey, JJ en Koos. Gedrieën verzorgen ze met hun vrolijke gekwebbel en soms pittige discussies voor een nieuwe, levendige episode van Einde van de Week Live. We hebben het natuurlijk over de talkshow waarin we steevast het belangrijkste game gerelateerde nieuws van de week doornemen. Met dit keer onder andere nieuws over Xbox's Project Helix, PlayStation en de PC ports, Assassin's Creed IV: Black Flag, de nieuwe RPG van Bandai Namco en de invasie van Israël door Iran in Call of Duty. Dit en nog veel meer onderwerpen komen voorbij in de Einde van de Week Live van vrijdag 6 maart 2026.Ubisoft erkent eindelijk dat de remake van Assassin's Creed IV: Black Flag 'in the making' isIn andere onderwerpen wordt gesproken over GTA 6 dat al ‘speelbaar' is, de studio achter Stellar Blade die onafhankelijk van PlayStation wil verder gaan en Karen, The Game. Plus we gaan de komende weken volop in op de release van Crimson Desert. Een game waarvan de hype-meter hoog staat. Gaat het spel het allemaal waarmaken? De eerste previews beloven veel goeds...Stap nu over op KPN internet en krijg een Switch 2 of PS5 cadeauVanaf deze week heeft KPN een actie lopen die je als weldenkend gamer bijna niet links kunt laten liggen. Als je namelijk overstapt naar KPN internet en een tweejarig abonnement afneemt, kun je als welkomstcadeau kiezen uit een Switch 2 of een PS5. En we weten dat veel mensen nog een Switch 2 willen halen. Plus de gamers die in november GTA 6 willen spelen en nog geen PS5 hebben; die zijn ook erg gebaat bij deze actie. Hier vind je alle info, de voorwaarden en de plek om deze deal te sluiten. En oh ja, glasvezel is natuurlijk de beste optie (als die tenminste bij jou in de straat ligt). Heb je geen lag meer en op sommige plekken tot 4 g/bit up snelheden. Wel zo fijn als je onbekommerd wil gamen.Scoor snel kaarten voor het concert van Joe Hisaishi met beelden en muziek van Studio GhibliFans van Studio Ghibli, opgelet: op 2 en 4 oktober dirigeert de Japanse Joe Hisaishi in de Ziggo Dome het Koninklijk Concertgebouworkest. Zij spelen dan een selectie uit zijn meest geliefde filmmuziek, waaronder tracks uit de prachtige Ghibli-films Spirited Away, Ponyo en Howl's Moving Castle. Deze meeslepende muziek wordt versterkt door beelden van de films op groot scherm. Dit is gamemuziek zoals je het wilt beleven. Het concert van 2 oktober is uitverkocht, maar voor het extra concert van 4 oktober zijn hier nog tickets beschikbaar. Wees snel, want op = op.

The monkeys bullying Punch are most definitely MAGA.Order our book, join our Substack, shop our merch, and more by clicking here: https://linktr.ee/ivehaditpodcast.Thank you to our sponsors:MSI Reproductive Choices: Go to https://MSIUnitedStates.org or you can just text MSI to Five Eleven Five Eleven.FX's Love Story: FX's Love Story: John F. Kennedy Jr. & Carolyn Bessette. Watch now on FX, Hulu, and Hulu on Disney+ for bundle subscribers.Jones Road Beauty: Use code Hadit at https://jonesroadbeauty.com to get a Free Shimmer Face Oil with your first purchase! #JonesRoadBeauty #adWildGrain: For a limited time, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life when you go to https://Wildgrain.com/HADIT to start your subscription today.This episode is brought to you by BetterHelp: Your emotional wellbeing matters. Find support and feel lighter in therapy. Sign up and get 10% off at https://BetterHelp.com/HADIT. Follow Us:I've Had It Podcast: @IvehaditpodcastJennifer Welch: @mizzwelchAngie "Pumps" Sullivan: @pumpspumpspumpsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Drie heren zitten er klaar voor in de studio van Gamekings. We hebben het over Daan, JJ en Koos. Gedrieën luiden ze het weekend voor je in met een nieuwe editie van Einde van de Week Live. EvdWL is de talkshow waarin we wekelijks het belangrijkste game gerelateerde nieuws doornemen. Met dit keer onder andere nieuws over Marvel's Wolverine, de releasedatum van GTA 6, Assassin's Creed, de chaos bij Xbox en de GaaS titel van PlayStation, Fairgame$. Dit en nog veel meer onderwerpen komen voorbij in de Einde van de Week Live van vrijdag 26 februari.Marvel's Wolverine komt 15 september uitIn deze aflevering wordt naast Wolverine en Assassin's Creed ook gesproken over de ontslagen die gevallen zijn bij de studio achter de game Skate, het gerucht dat Bluepoint wilde werken aan een Bloodborne remake maar dat PlayStation dat niet wilde dit feestjaar en een opmerkelijk patent van Sony.Schaf de Vector 16 HX gaming laptop aan en krijg er Resident Evil Requiem gratis bijMSI showt deze week de Vector 16 HX. Het betreft een gaming laptop met daarin een Intel Core Ultra 7 (Series 2) processor, een NVIDIA GeForce RTX 5070 Ti GPU, een 1TB SSD, een 16” 240Hz QHD display, 24-zone RGB toetsenbord en een Thunderbolt 5 aansluiting. Deze pittige laptop is nu bij MeGekko verkrijgbaar voor een scherpe prijs én je krijgt er ook nog eens Resident Evil Requiem bij. En je hebt de review gezien …Speel vanaf 27 februari het gruwelijke Resident Evil RequiemHet zijn momenteel hoogtijdagen voor de ouderwetse gamer. De gamer die van goede single player games houdt met uitdagende actie en een sterk verhaal. Crimson Desert komt eraan, Nioh 3 is net uit en aanstaande donderdag is het tijd voor de release van Resident Evil Requiem. Het negende deel van de beruchte franchise van Capcom, staat klaar om je de stuipen op het lijf te jagen. Aanstaande woensdag hebben we vanaf 16:00 de review voor je klaarstaan.Stap nu over op KPN internet en krijg een Switch 2 of PS5 cadeauVanaf deze week heeft KPN een actie lopen die je als weldenkend gamer bijna niet links kunt laten liggen. Als je namelijk overstapt naar KPN internet en een tweejarig abonnement afneemt, kun je als welkomstcadeau kiezen uit een Switch 2 of een PS5. En we weten dat veel mensen nog een Switch 2 willen halen. Plus de gamers die in november GTA 6 willen spelen en nog geen PS5 hebben; die zijn ook erg gebaat bij deze actie. Hier vind je alle info, de voorwaarden en de plek om deze deal te sluiten. En oh ja, glasvezel is natuurlijk de beste optie (als die tenminste bij jou in de straat ligt). Heb je geen lag meer en op sommige plekken tot 4 g/bit up snelheden. Wel zo fijn als je onbekommerd wil gamen.

Tonight, we're breaking down Bill Clinton's testimony in the ongoing fallout surrounding Jeffrey Epstein. What did Clinton say? What was clarified, and what still raises serious questions? And as more details emerge, many Americans are asking why the sitting president, Donald Trump, hasn't been called in for questioning. Especially as his name reportedly appears more than 38,000 times across the Epstein files? Don breaks down the facts, the legal realities, and the political implications. Join us live! This episode is sponsored by 120Life. Go to https://120Life.com and use my code DON for 20% off. Try it risk-free for two weeks. If your blood pressure doesn't come down, you get a full refund. This episode is brought to you by Surfshark. Go to https://surfshark.com/donlemon and use code donlemon at checkout to get 4 extra months of Surfshark VPN! This episode is sponsored by MSI. Donate today Text LEMON to 511511, or https://MSIUnitedStates.org This episode is sponsored by Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon Learn more about your ad choices. Visit megaphone.fm/adchoices

This morning we're breaking down the latest news in the ever-unfolding Jeffrey Epstein saga as Bill Clinton testifies about his relationship and involvement. What will be revealed? What has already been confirmed? And what does this mean for the broader web of powerful names connected to this case? And let's be honest, while past presidents are being questioned, many Americans are wondering whether people currently in power (looking at you, Donald Trump) will ever face meaningful scrutiny or accountability for their own connections. Then we pivot to a bombshell media shakeup: Netflix has reportedly backed out of a bid for Warner Bros., clearing a path for Paramount to acquire it. What does that mean for the future of media consolidation? Who controls what we watch and how worried should we be. Joining us to unpack it all is Founding Editor of Mediaite.com Colby Hall along with Semafor's Max Tani and Ben Smith. This episode is sponsored by 120Life. Go to https://120Life.com and use my code DON for 20% off. Try it risk-free for two weeks. If your blood pressure doesn't come down, you get a full refund. This episode is brought to you by Surfshark. Go to https://surfshark.com/donlemon and use code donlemon at checkout to get 4 extra months of Surfshark VPN! This episode is sponsored by MSI. Donate today Text LEMON to 511511, or https://MSIUnitedStates.org This episode is sponsored by Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon Learn more about your ad choices. Visit megaphone.fm/adchoices

Tonight, Don breaks down the testimony from Hillary Clinton related to the growing fallout from the Jeffrey Epstein case. What exactly was said? And how does this testimony reshape the broader conversation around accountability, transparency, and the powerful figures whose names continue to surface? Then, we pivot to new reporting from The Washington Post highlighting serious election integrity concerns. Donald Trump is seeking expanded executive authority over elections. What would that mean legally? How much authority does a president actually have over federal elections? And how concerned should Americans be? This episode is sponsored by 120Life. Go to https://120Life.com and use my code DON for 20% off. Try it risk-free for two weeks. If your blood pressure doesn't come down, you get a full refund. This episode is sponsored by MSI. Donate today Text LEMON to 511511, or https://MSIUnitedStates.org This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon This episode is sponsored by Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. This episode is brought to you by Surfshark. Go to https://surfshark.com/donlemon and use code donlemon at checkout to get 4 extra months of Surfshark VPN! Learn more about your ad choices. Visit megaphone.fm/adchoices

After the Clintons initially rejected subpoenas to appear in front of congress in regards to the Epstein files, and after the GOP rejected the Clintons' desire to testify publicly, today Hillary Clinton will do so in front of a House panel. This testimony will be recorded on camera but behind closed doors. Tomorrow, former president Bill Clinton is scheduled to testify as well. With the Clintons being willing to share their side of the Epstein story, will we ever hear from the Trump's in the same way? Probably not, but their silence says volumes. Join Don to break down this story and more!

Tonight we are joined by Rep. Al Green to discuss his protest and subsequent removal from last night's State of the Union address. The congressman held up a sign which read "Black People Aren't Apes," a reference to a Trump tweet which depicted the Obamas as apes in a meme. Also, former Treasure Secretary and Harvard professor Larry Summers has resigned from his professorship at the university for his involvement with Jeffery Epstein. With more and more folks with ties to Epstein are losing jobs and facing accountability, when will the Epstein files affect those in the Trump administration? Join Don to break these stories down.

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Good morning Lemon Nation. Last night was less an address about the state of our country and more a medal ceremony to those who like the President. Trump handed out military honors and even presented our U.S. men's Olympic hockey team goalie with a medal of freedom. When he wasn't putting on a show for his cult, Trump was back to his favorite fodder for lies: Somalis in Minnesota, tariffs, drug prices, Democrats, Iran, the list goes on. Join Don to break down this embarrassment disguised as a presidential speech.

Tonight, we're diving into the continued global fallout from the Epstein files. Peter Mandelson, a former U.K. ambassador to the United States, has reportedly been arrested by British authorities over his ties to Jeffrey Epstein. Mandelson is the latest powerful figure to face scrutiny as investigations move forward overseas. So the question is obvious: who's next? As international authorities take action, will anyone connected within MAGA world ever face real accountability? Or will the Epstein scandal continue to produce consequences everywhere but here? We break down what this means, what could happen next, and why justice still feels uneven.

This morning, we're diving into explosive new reporting from NPR alleging that the U.S. Department of Justice withheld and removed certain Epstein-related documents from public databases, including files that reference allegations involving Donald Trump. The report claims materials tied to accusations against Jeffrey Epstein that also mention Trump were taken down or never fully released. As other countries pursue investigations and consequences for officials connected to Epstein, the contrast here is striking. Will anyone in MAGA world ever face accountability? Will victims ever see justice? Then we pivot to tonight's State of the Union. What exactly is the state of the union? We'll break down the stakes before the speech even begins.

This morning, we're talking about a White House that looks desperate. As Donald Trump's approval ratings slide, the administration seems to think the solution is… sports cosplay? From Kash Patel partying with athletes like he just got drafted, to Trump posting an AI-generated video of himself scoring a hockey goal, the cringe factor is off the charts. Is this just a distraction from sinking numbers and mounting criticism? We'll break down the polling, the optics, and why trying to co-opt sports culture might say more about panic than popularity.

David Raymond and Emily Holle, senior director sales and marketing and creative director with MSI, respectively, and Kemp Harr showcase market trends and how they work to fill those needs with innovations and new products.

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Net als vorige week vrijdag en al die vrijdagen ervoor de week, zitten er drie heren klaar achter de kenmerkende desk van Gamekings. We hebben het over Huey, JJ en Koos. Ze gaan gezamenlijk het weekend inluiden met een nieuwe editie van Einde van de Week Live. EvdWL is de talkshow waarin we wekelijks het belangrijkste game gerelateerde nieuws doornemen. Met dit keer onder andere nieuws over Elder Scrolls 6 en een nieuwe engine. Verder het zesjarig bestaan van GeForce Now, de sluiting van Bluepoint Games en een nieuw onderzoek dat uitwijst dat gamen het qua aandacht aflegt tegen gokken, porno en crypto. Dit en vele andere gespreksonderwerpen komen voorbij in deze Einde van de Week Live van vrijdag 20 februari.Elder Scrolls 6 krijgt een nieuwe engineIn dit feestjaar kijken de drie ook terug op gaming rond de eeuwwisseling. De jaren waarin Gamekings begon en gevormd werd. Plus natuurlijk aan het einde altijd een luchtig stukje vermaak in de vorm van de rubriek Cool & Serious Uncool.Schaf de Katana 15 HX gaming laptop aan en krijg er Resident Evil Requiem gratis bijMSI zet deze week de Katana 15 HX in de spotlights. Het betreft een gaming laptop met daarin een 14e generatie Intel Core i7 HX processor, een NVIDIA GeForce RTX 5070 GPU, een 1TB SSD, een 15.6” 144Hz Full HD panel, 2x Type-C en 3x Type-A USB aansluitingen en een 4-zone RGB toetsenbord. Deze krachtige laptop is nu bij Bol voor een scherpe prijs verkrijgbaar en je krijgt er ook nog eens Resident Evil Requiem bij. En dat wil je...Stap nu over op KPN internet en krijg een Switch 2 of PS5 cadeauVanaf deze week heeft KPN een actie lopen die je als weldenkend gamer bijna niet links kunt laten liggen. Als je namelijk overstapt naar KPN internet en een tweejarig abonnement afneemt, kun je als welkomstcadeau kiezen uit een Switch 2 of een PS5. En we weten dat veel mensen nog een Switch 2 willen halen. Plus de gamers die in november GTA 6 willen spelen en nog geen PS5 hebben; die zijn ook erg gebaat bij deze actie. Hier vind je alle info, de voorwaarden en de plek om deze deal te sluiten. En oh ja, glasvezel is natuurlijk de beste optie (als die tenminste bij jou in de straat ligt). Heb je geen lag meer en op sommige plekken tot 4 g/bit up snelheden. Wel zo fijn als je onbekommerd wil gamen.

Today we have Ziv Mador, VP of Security Research from LevelBlue SpiderLabs discussing their work on "SpiderLabs IDs New Banking Trojan Distributed Through WhatsApp." Researchers at LevelBlue SpiderLabs have identified a new Brazilian banking Trojan dubbed Eternidade Stealer, spread through WhatsApp hijacking and social engineering campaigns that use a Python-based worm to steal contacts and distribute malicious MSI installers. The Delphi-compiled malware targets Brazilian victims, profiles infected systems, dynamically retrieves its command-and-control server via IMAP email, and deploys banking overlays to harvest credentials from financial institutions and cryptocurrency platforms. The campaign reflects the continued evolution of Brazil's cybercrime ecosystem, combining WhatsApp propagation, geofencing, encrypted C2 communications, and process injection to maintain stealth and persistence. The research can be found here: SpiderLabs IDs New Banking Trojan Distributed Through WhatsApp Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we have Ziv Mador, VP of Security Research from LevelBlue SpiderLabs discussing their work on "SpiderLabs IDs New Banking Trojan Distributed Through WhatsApp." Researchers at LevelBlue SpiderLabs have identified a new Brazilian banking Trojan dubbed Eternidade Stealer, spread through WhatsApp hijacking and social engineering campaigns that use a Python-based worm to steal contacts and distribute malicious MSI installers. The Delphi-compiled malware targets Brazilian victims, profiles infected systems, dynamically retrieves its command-and-control server via IMAP email, and deploys banking overlays to harvest credentials from financial institutions and cryptocurrency platforms. The campaign reflects the continued evolution of Brazil's cybercrime ecosystem, combining WhatsApp propagation, geofencing, encrypted C2 communications, and process injection to maintain stealth and persistence. The research can be found here: SpiderLabs IDs New Banking Trojan Distributed Through WhatsApp Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we're bringing you an extended live stream. Don is in court, and we'll have coverage throughout the day with real-time updates, analysis, and reactions from friends of the show. This case goes far beyond one journalist, it's about the freedom of the press, the right to report on protests, and whether the government can intimidate members of the media for doing their jobs.

This morning, we're covering a major development: Don is appearing in court after the U.S. Department of Justice brought charges tied to his coverage of a protest at a Minneapolis church. This isn't just about one case. It's about the freedom of speech and the freedom of the press and whether journalists can report on protests without facing retaliation from the government. We'll break down what's at stake and why this moment matters far beyond one courtroom.

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het is tijd om het weekend feestelijk in te luiden. We hebben de vrije dagen met z'n allen verdiend. Dat inluiden doen we met een verse editie van Einde van de Week Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie doornemen. Vandaag zitten Huey, JJ en Koos achter de desk. Never change a winning team immers. Het hoofddeel van deze aflevering draait om de PlayStation State of Play die op donderdagavond werd uitgezonden. Vooraf werd gesteld dat dit de langste editie ooit zou gaan worden. Lang kan leuk zijn, maar als de games en de trailers tegenvallen, dan kan lang ook saai worden. Wat is het geworden? Wat waren de beste aankondigingen van de avond? Je krijgt het antwoord in de Einde van de Week Live van vrijdag 13 februari 2026.Alle hoogte- en dieptepunten van de PlayStation State of Play op een rijIn ander nieuws praten de heren ook over de nieuwe Silent Hill die mogelijk sneller komt dan verwacht, de prima verkoopcijfers van Nioh 3, Kingdom Come Deliverance II en Lies of P, de controverse rond het tweede seizoen van Battlefield 6 en een crimineel die baalt omdat hij de bak in moet en dus niet GTA 6 kan spelen.Krijg 200 euro korting + Resident Evil Requiem bij aanschaf van de Vector 16HX AI gaming laptopMSI zet deze week de Vector 16 HX AI in het zonnetje. Deze gaming laptop is goed krachtig dankzij een Intel Core Ultra 9 processor, een NVIDIA GeForce RTX 5080, een 240Hz QHD+ display, een 1TB SSD en een 24-zone RGB toetsenbord. Deze laptop is hier bij Informatique te koop met 200 euro korting. Plus je krijgt er Resident Evil Requiem bij.Scoor kaarten voor het concert van de Zweedse metal sensatie Avatar in de Ziggo DomeOp vrijdag 20 februari gaat de Zweedse metalband Avatar de Ziggo Dome zwaar op zijn grondvesten doen schudden.  Na een reeks shows in de zomer van 2025 met metalhelden Iron Maiden, brengt de Zweedse band een vernieuwde liveproductie vol nummers van vroeger en nu naar Amsterdam. De band heeft aangekondigd al hun vorige grenzen te willen doorbreken. Neem je stoelriemen dus maar mee. Wil je bij dit concert aanwezig zijn, dan kun je hier de kaarten kopen.

Another day, another unhinged and dangerous instance of Donald Trump spouting lies from a podium. This time he pretended to not know much about two big recent news items: Howard Lutnick caught lying about his relationship to Jeffrey Epstein, and the racist, viral video that a Trump "staffer" posted last week depicting the Obamas as apes. Isn't this the president who never sleeps and spends most of his free time watching news coverage and tweeting? Join Don at 5pm EST to break it all down!

Today Attorney General Pam Bondi testified in front of the House Judiciary Committee and it did not go well for her. Bondi lashed out at every democrat who questioned her and refused to answer straight forward questions pertaining to the Epstein files. But was her performance good enough for her presidential audience of one? Is the MAGA base buying any of this? And what did she have to say about Don Lemon? Join Don and a great panel of guests to break down all that was said during this 5 hour congressional hearing.

This morning, we're diving into the aftermath of Pam Bondi's House hearing, and let's just say... it was not her finest hour. Questions were asked, but very few were actually answered. Instead, we got deflection, finger-pointing, and a masterclass in blaming literally everyone else. We'll break down the most embarrassing moments, what it says about the handling of the Epstein files, and why accountability still feels like a foreign concept. Joining Don to unpack the mess are Tim Miller of The Bulwark and Jennifer Welch of the I've Had It podcast.

This morning, we're following the live House hearing as Pam Bondi testifies amid mounting scrutiny over the handling of the Epstein files. The rollout has been chaotic, the redactions heavy, and the questions keep piling up. Will we get real answers today or more deflection? Why has this process been such a mess? And is anyone, anywhere, actually going to face accountability? Joining us this morning are friends of the show Monique Pressley, Tara Palmeri, and Keith Edwards to help us break this all down. This episode is sponsored by MSI. Text LEMON to 511511, or go to https://MSIUnitedStates.org. A gift of $39 is enough to give 6 women contraception for a year! Think of that. Please help them out. This episode is brought to you Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. This episode is sponsored by Graza. Take your food to the next level with Graza. Visit https://graza.co/LEMON and use promo code LEMON today for 10% off your first order of olive oil! This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon WE HAVE MERCH!! Purchase here: https://don-lemon-merch-store.myshopify.com/ WATCH & Subscribe on YouTube @TheDonLemonShow! Become a member of our channel here: https://www.youtube.com/channel/UCXs0PlIGUDSXfBaF7j-1euA/join Follow Don on Substack! Listen on Apple, Spotify and iHeart Radio! Learn more about your ad choices. Visit megaphone.fm/adchoices

Got a question or comment? Message us here!Attackers are hiding remote access trojans (RATs) inside malicious MSI installers disguised as legit software, and it's surging in early 2026. We break down how these phishing attacks bypass EDR, what to look for, and how SOC teams can stop them before they turn into full-blown breaches. Support the showWatch full episodes at youtube.com/@aliascybersecurity.Listen on Apple Podcasts, Spotify and anywhere you get your podcasts.

Tonight we will be focusing on the new revelations and new denials from a white house engulfed in the Epstein scandal. Now that congress is getting the chance to view some unredacted files we are learning much more about what, and who, is being hidden from the public. An all-star panel of journalists, legal minds, and political thinkers will be here to discuss. Also, new surveillance footage from the home of Nancy Guthrie has been released. Don will be joined by a former FBI official to break down what this video means and what we can learn from it. This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon This episode is sponsored by MSI. Text LEMON to 511511, or go to https://MSIUnitedStates.org. A gift of $39 is enough to give 6 women contraception for a year! Think of that. Please help them out. This episode is brought to you Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. This episode is sponsored by Graza. Take your food to the next level with Graza. Visit https://graza.co/LEMON and use promo code LEMON today for 10% off your first order of olive oil! NMLS 182334, nmlsconsumeraccess.org. APR for rates in the 5s start at 6.196% for well qualified borrowers. Call 888-675-4090, for details about credit costs and terms. Or AmericanFinancing.net/Lemon Learn more about your ad choices. Visit megaphone.fm/adchoices

Tonight, we're breaking down the latest bombshell revelations from the Epstein files, and the denial is getting laughable. Donald Trump's name reportedly appears more than 38,000 times, yet MAGA is still pretending this is all a coincidence. The math isn't mathing. Will anyone named in these files ever face real accountability? Will the victims ever see justice? Or will power and politics keep doing what they do best, running interference? Joining Don to cut through the spin is journalist and friend of the show Tara Palmeri.

This morning, we're continuing to break down the fallout from the halftime show and wow, MAGA is still losing it. The outrage has gone far beyond music criticism and is once again exposing the racism and cultural panic that shows up anytime they don't control the spotlight. And then there was the attempted counter-programming. Turning Point USA's alternate halftime show starring Kid Rock. Let's be honest, it was awkward, chaotic, and painfully unpopular. While Bad Bunny dominated the moment, MAGA managed to turn a cultural event into yet another self-own. This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon This episode is sponsored by MSI. Text LEMON to 511511, or go to https://MSIUnitedStates.org. A gift of $39 is enough to give 6 women contraception for a year! Think of that. Please help them out. This episode is brought to you Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. This episode is sponsored by Graza. Take your food to the next level with Graza. Visit https://graza.co/LEMON and use promo code LEMON today for 10% off your first order of olive oil! Learn more about your ad choices. Visit megaphone.fm/adchoices

I sit down with Dr Mev Dominguez, Project Group Leader Inherited and Familial Cancer at the University of Oslo and Director of the Predi Lynch Project.  Starting in May 2025, lasting for 6 years, there are 28 partners from 16 European countries acting and working together.  Liquid biopsy every year, urine, MSI plus, vaginal swabs, and stool samples will be compiled over 27 clinical centers.  Important factors include social and financial acceptability.  Open for lynch syndrome patients over age 35 but no cancer for the last year.  A biobank will be created, and analysis will be done using AI.  Everything should be followed via the Predi-lynch.edu web site.  

This morning, we're diving into MAGA's full-blown meltdown over Bad Bunny's halftime show. While millions tuned in, the right lost its mind, and in a truly desperate move, tried to roll out a rival show via Turning Point USA featuring Kid Rock. Let's be honest, nobody wanted that. We'll break down the outrage, the cringe, and why culture keeps leaving MAGA behind no matter how loud they get. This episode is sponsored by Graza. Take your food to the next level with Graza Olive Oil. Visit https://graza.co/DON and use promo code DON today for 20% off your first order! This episode is brought to you by Shopify. Sign up for your one-dollar-per-month trial and start selling today at https://SHOPIFY.COM/lemon This episode is sponsored by MSI. Text LEMON to 511511, or go to https://MSIUnitedStates.org. A gift of $39 is enough to give 6 women contraception for a year! Think of that. Please help them out. This episode is brought to you Wildgrain. Right now, Wildgrain is offering our listeners $30 off your first box - PLUS free Croissants for life - when you go to https://Wildgrain.com/LEMON to start your subscription today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Ga maar goed zitten voor het startschot van het weekend. Anderhalf uur aan knus gekwebbel over videogames kietelt binnen enkele seconden jouw trommelvliezen. Huey, JJ en Koos zitten in de studio klaar. Ready om een nieuwe editie op te nemen van Einde van de Week Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie, de kijkers, doornemen. We hebben een fijn lijstje aan topics voor je klaarstaan. Zo discussiëren de drie over de Nintendo Direct die op donderdag werd uitgezonden en die geheel gewijd was aan games van third party publishers. Ter sprake komt ook de nieuwste game van Guerilla, Horizon Hunters Gathering, en het besluit van Blizzard om Overwatch 2 voortaan Overwatch te noemen. Dit alles en meer ga je beleven in de Einde van de Week Live van vrijdag 5 december 2025.Guerrilla spraakmakend met hun nieuwe game ‘Horizon Hunters Gathering'In ander nieuws babbelen de drie vrolijk over de nieuwe beelden van de GTA-kloon Samson, het ontbreken van een Fallout 3 shadow drop en de controverse rond de Definitive Edition van The Division. Plus natuurlijk een dosis wekelijkse malheid in de vorm van Cool of Serieus Uncool. Laat het weekend maar beginnen. Wij zijn er helemaal klaar voor.Krijg 150 euro korting bij aanschaf van de Cyborg 15 gaming laptopMSI zet deze week de Cyborg 15 in de spotlights. Deze laptop heeft namelijk een hele fijne prijs dankzij de BTW-vrije dagen bij MediaMarkt. Onder de befaamde motorkap bevinden zich een Intel Core 7 240H processor, een NVIDIA GeForce RTX 5060 GPU, een 512GB SSD en een 4-zone RGB keyboard. De prestaties kun je afzien op een 15.6” full hd 144 Hz paneel. Deze laptop is hier tijdelijk met 150 euro korting te koop.Scoor kaarten voor het concert van de Wu-Tang Clan in de Ziggo DomeOp maandag 2 maart gaat de Wu-Tang Clan de Ziggo Dome op zijn grondvesten doen schudden. De rapformatie is een absolute favoriet onder de liefhebbers van hiphop bij ons op de redactie. Om hun muziek en teksten, maar ook om hun bezigheden in en rondom videogames. Ze maken bijvoorbeeld onderdeel uit van de fantastische Def Jam reeks en hebben zelf ook games gemaakt. Een daarvan komt binnenkort uit. Wil je bij het concert van de Clan aanwezig zijn, dan kun je hier de kaarten kopen.

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Laat het nu echt tijd zijn voor het weekend. Sneeuw of geen sneeuw. We hebben met zijn allen behoefte aan een aantal vrije dagen. En die vrije dagen luiden we in met een nieuwe editie van Einde van de Week Live. De talkshow waarin we op luchtige wijze het game-gerelateerde nieuws van de week doornemen. Achter de desk zitten Huey, JJ & Skate. Zij gaan jou het komende dikke uur vermaken met gezellig gekwebbel over games. Zo praten ze over een aantal nieuwe games die uit China komen, de frustratie van de makers van Baldur's Gate 3 over de communityreviews op platformen als Steam en Metacritic en de nieuwste beelden van Crimson Desert. Dit alles en meer ga je zien en horen in de Einde van de Week Live van vrijdag 30 januari 2026.Zijn nieuwe beelden Crimson Desert ‘too good to be true'Andere topics gaan over een mysterieuze website die door Team Bloober is opgezet en aftelt naar Valentijnsdag. Wat willen ze hiermee zeggen? De tweede trailer van de nieuwe Mario Movie wordt bekeken en de drie gaan in op de vraag hoe hoog de prijs mag zijn van een game die zich in Early Access bevindt? Dit alles en meer zie je in deze video voorbij komen.Betaal tijdelijk minder dan 1000 euro voor de Cyborg 15 gaming laptopMSI zet deze week de Cyborg 15 in de spotlights. Deze laptop heeft namelijk een hele fijne prijs dankzij de BTW-vrije dagen bij MediaMarkt. Onder de befaamde motorkap bevinden zich een Intel Core 7 240H processor, een NVIDIA GeForce RTX 5060 GPU, een 512GB SSD en een 4-zone RGB keyboard. De prestaties kun je afzien op een 15.6” full hd 144 Hz paneel. Deze laptop is hier tijdelijk voor slechts 990 euro te koop.

This show has been flagged as Clean by the host. Development isn't over until it's packaged Most software development I've done has been utilities for highly specific workflows. I've written code to ensure that metadata for a company's custom file format gets copied along with the rest of the data when the file gets archived, code that ensures a search field doesn't mangle input, lots of Git hooks, file converters, parsers, and of course my fair share of dirty hacks. Because most software projects I work on are designed for a specific task, very few of them have required packaging. My utilities have been either integrated into a larger code base I'm not responsible for, or else distributed across an infrastructure by an admin. It's like a magic trick, which has made my life conveniently easier but, as magic does, it has also tricked me into thinking that my development work is done once I can prove that my code does its job. The reality is that code development isn't actually done until you can deliver it to your users in a format they can install. I don't think I'm alone in forgetting that software delivery is the real final product. There are many reasons some developers stop short of providing an installable package for the code they've worked on for weeks or months or years. First of all, packaging is work, and after writing and troubleshooting code for months, sometimes you just want your work to be over just as soon as everything functions as expected. Secondly, there are a lot of software package formats out there, regardless of what platform you're delivering to. However, I view packaging as part of quality assurance. There are lots of benefits you gain by packaging your code into an installer, and you don't have to target every package format. In fact, you get the benefits of packaging by creating just one package. Checking for consistency When you package your code as an installable file, whether it's an RPM file or a Bash script or a Flatpak or AppImage or EXE or MSI or anything else, you are checking your code base for consistency. Pick whatever package format you're most comfortable with, or the one you think represents the bulk of your target audience, and you're sure to find that the package tooling expects to be automated. Nobody wants to start packaging from scratch every time they update code, so naturally packaging tools are designed to be configured once for a specific code base and then to create updated packages each time the code base is updated. If you're building a package for your project and discover that you have to manually intervene, then you've discovered a bug in your code. Imagine that you've got a project repository with a name in camel-case. You hadn't noticed before, but your code refers to itself in a mix of lowercase and camel-case. Your package build grinds to a halt because a variable used by the packaging tools suddenly can't find your code base because it was set to a lowercase title but the archive of your code uses camel-case. If this happens to you, it's also going to happen for every software packager trying to help you deliver your project to their users. Fix it for yourself, and you've fixed it for everyone. Discover surprise dependencies For decades, one of the most common problems of software troubleshooting has been the phrase “well, it works on my machine.” No matter how many tools we developers have at our disposal to make it easy to build and run software on a clean system, it's still common to accidentally deliver software with surprise dependencies. It's easy to forget to revert to a clean snapshot in a virtual machine, or to use a container that just happens to have a more recent version of a library than you'd realised, or to get the path of an important executable wrong in a script, or to forget that not all computers ship with a thing you take for granted. Not all packaging tools are immune to this problem, but very robust ones (like RPM and DEB, Flatpak, and AppImage) are. I can't count the times I've tried to deliver an RPM only to be reminded by rpmbuild that I haven't included the -devel version of a dependency (many Linux distributions separate development libraries from binaries.) You may not literally fix every problem with dependency management by building a single package, but you can clearly identify what your code requires. It only takes a single warning from your packaging tool for you to add a note to other packagers about what they must include in their own builds. As an additional bonus, it's also a good reminder to double check the licenses your project is using. In the haze of desperate hacking to get something to just-work-already, it's helpful to get a gentle reminder that you've linked to a library with a different license than everything else. Few packaging tools (if any?) detect licensing requirements directly, but sometimes all it takes is a reminder that you're using a library that comes from a non-standard repo for you to remember to review licensing. Every package is an example package Once you've packaged your code once, you create an example for everyone coming to your project to turn it into a package of their own. It doesn't matter whether your example package is an RPM or a DEB or just a TGZ for a front-end like SlackBuild or Arch's AUR, it's the interaction between a packaging system and the input script that counts. Even a novice package maintainer is likely to be able to reverse engineer a packaging script enough to reuse the same logic for their own package. Here's the build and install section of the RPM for GNU Hello: %prep %autosetup %build %configure make %{?_smp_mflags} %install %make_install %find_lang %{name} rm -f %{buildroot}/%{_infodir}/dir %post /sbin/install-info %{_infodir}/%{name}.info %{_infodir}/dir || : Here's the GNU Hello build script for Arch Linux: source=(https://ftp.gnu.org/gnu/hello/$pkgname-$pkgver.tar.gz) md5sums=('5cf598783b9541527e17c9b5e525b7eb') build(){ cd "$pkgname-$pkgver" ./configure --prefix=/usr make } package(){ cd "$pkgname-$pkgver" make DESTDIR="$pkgdir/" install } There are differences, but you can see the shared logic. There are macros or functions that abstract some common steps of the build process, there are variables to ensure consistency, and they both benefit from using automake as provided by the source code. Armed with these examples, you could probably write a DEB package or Flatpak ref for GNU Hello in an afternoon. Package your code at least once Packaging is quality assurance. Even though a packaging system is really just a front-end for whatever build system your code uses anyway, the rigour of creating a repeatable and automated process for delivering your project is a helpful exercise. It benefits your project, and it benefits the people eager to deliver your project to other users. Software development isn't over until it's packaged.Shownotes taken from https://www.both.org/?p=13264Provide feedback on this episode.

Dr. Mary-Ellen Taplin joins the podcast to discuss the latest changes to the living guideline on metastatic castration-resistant prostate cancer (mCRPC). She reviews new treatment options for patients treated with ADT alone, ADT and an ARPI, ADT and docetaxel, and ADT, an ARPI, and docetaxel whose disease has progressed to mCRPC and the evidence that underpins these changes. Dr. Taplin highlights the updated algorithms within the guideline and the living format which will provide rapid, up-to-date, evidence-based information for clinicians and patients. Read the full living guideline update, "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." at www.asco.org/genitourinary-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02693 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Mary-Ellen Taplin from Dana-Farber Cancer Institute, lead author on "Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1." Thank you for being here today, Dr. Taplin. Dr. Mary-Ellen Taplin: Thank you, Brittany. It is a pleasure. Brittany Harvey: Before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Taplin who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To dive into the content here and what we are here today to talk about, this living clinical practice guideline for systemic therapy for patients with metastatic castration-resistant prostate cancer is updated on an ongoing basis. Dr. Taplin, what prompted this latest update to the recommendations? Dr. Mary-Ellen Taplin: Thank you, Brittany. Several things prompted the latest update. There have been several phase III trials that have been practice-changing that have resulted in the last several years that needed to be added to the guidelines to inform clinicians of comprehensive treatment options. Brittany Harvey: Great, and it is great to have this updated guideline for readers. I would like to review the changes to the recommendations in this latest iteration across the patient populations that are outlined in the guideline. So, starting with: What are the updated recommendations for patients previously treated with androgen deprivation therapy alone whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: A nice feature of this guideline is that in addition to the tables, which provide detailed options, is at the end of the guidelines, our readers will find very clear algorithms that describe past treatment scenarios that patients could have had and then outline their treatment options. So it is very clear. Our clinicians will love these algorithms. And one of the changes for the disease state that you mentioned, which is the least treated castration-resistant state of prostate cancer which is previously treated with ADT alone, is that we recommend testing for mutations in the HRR, homologous recombination repair, genes. And the ones that are specifically known and applicable to prostate cancer are the BRCA genes. So there is clear recommendation of testing to remind us, as treating physicians, that now is the time, if it hasn't been done before, to institute both germline and somatic testing. And somatic testing, if it can be done on tissue, is preferable, but if not, the liquid biopsy approaches, the ctDNA approaches, have now advanced to the point that most patients with metastatic prostate cancer will be able to successfully have testing on the liquid biopsies. So that is number one, testing. And then the new treatment options include, if a patient does have an HRR gene alteration, and maybe about 20-25 percent of patients will be in that category, the combinations of an androgen pathway inhibitor and a PARP inhibitor are now treatment options. So for instance, talazoparib and enzalutamide; olaparib and abiraterone; or niraparib and abiraterone are some of the newer treatment options if the patient is HRR-positive. So, Brittany, in regard to patients treated with ADT alone, another new treatment option is the combination of radium-223 with enzalutamide. This is data based on the PEACE-3 trial which did show both an rPFS and OS benefit. For the patient who is HRR-negative and has previously not had an ARPI, just ADT alone, the combination of radium and enzalutamide is a new recommendation added to the algorithm. Brittany Harvey: Great. Thank you for reviewing those options for that patient population. And as you mentioned, I think those algorithms are very helpful as figures in the document. They are clear and can be used as at-a-glance tools for clinicians in their busy clinics. So then the next patient population that the guideline addresses: What is new for patients previously treated with androgen deprivation therapy and an androgen receptor pathway inhibitor whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Right, so there are several new treatment options. So one is lutetium-PSMA-617, the trade name of which is Pluvicto. So that has now been FDA approved to use after progression on an AR pathway inhibitor and prior to the use of docetaxel chemotherapy. Brittany Harvey: Thank you for reviewing that new option for patients treated with androgen deprivation therapy and an ARPI whose disease has progressed. So then moving into the next set of recommendations, what does the panel now recommend for patients previously treated with androgen deprivation therapy and docetaxel whose disease has progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: The next group of patients is those treated with ADT and docetaxel but haven't had an AR pathway inhibitor. Treatment options, again the HRR testing is important. So all patients with metastatic castration-resistant prostate cancer should be considered for both germline and somatic testing. I will repeat that. And if they are BRCA mutation positive, then the option of talazoparib and enzalutamide; olaparib and abiraterone; and niraparib and abiraterone.  So the AR pathway inhibitors plus the PARPs. There are three choices, so that can be somewhat complicated to think through, but most practitioners will get familiar with one of those combinations and be their go-to. So those are for BRCA-positive or HRR-positive. The talazoparib/enzalutamide trial also included non-BRCA HRR-positive gene mutations. And if they are HRR-negative, the option that we discussed above of radium and enzalutamide is new to the guideline. Brittany Harvey: Great. And then the last category of patients that is addressed in this update: What has changed for patients previously treated with androgen deprivation therapy, an androgen receptor pathway inhibitor, and docetaxel whose disease has now progressed to metastatic castration-resistant prostate cancer? Dr. Mary-Ellen Taplin: Well, in this space, patients who are heavily pretreated with ADT and ARPI, one or even two, and chemotherapy, generally with docetaxel, the recommendations are not new within the last year or two. And they include Pluvicto; a PARP inhibitor if HRR-positive and they have not had one; second-line chemotherapy such as cabazitaxel. And if they are a very rare group and they have been sequenced and they are MSI-high, then considering a PD-1 inhibitor such as pembrolizumab can be considered. I will note that this is a very small percentage of mCRPC patients, probably in the order of 5 percent or less. Brittany Harvey: Understood. And I appreciate you reviewing the recommendations across all of these patient populations. It sounds like some of the key points is that HRR testing is very important for this patient population, and that the algorithms and the tables in the manuscript provide the full list of options that clinicians and patients can refer to. Dr. Mary-Ellen Taplin: Those are the highlights. And I will note in the tables, all the sections have "Special Considerations" sections because patients never fall into the black and white of one category. And those practical information or special situations sections of each of the recommendations can also help clinicians think about the individual patient in front of them and how they might choose one therapy over another since there are generally choices in all of these treatment situations. Brittany Harvey: Absolutely. That information for the individualized patient-clinician decision-making is really key when, as you said, there is a list of options to choose from. So in your view, what should clinicians know as they implement this living guideline update, and how do these changes impact patients? Dr. Mary-Ellen Taplin: I am so excited about this living document. ASCO has invested to developing the software to, in real time and iteratively, assess the new data that is published in prostate cancer and other diseases. So now we don't have to wait many years for the next guideline to come out. The guidelines will be updated every six months in prostate cancer based on this automatic search of the literature and a standing panel of both academic and community experts in prostate cancer treatment. So we no longer have to wait. That is what makes this guideline stand out to other guidelines. And in the digestible format that we have made, a clinician can seek out the table and read some details, seek out practical information for the recommendations, or they can just go right to the clear figure algorithm and take a quick snapshot. "Yep, I need to do HR testing. Done. Oh, okay. HR-positive or negative, these are my options," and then think about the individual patient in front of them when there is more than one option. For instance, a patient with cardiovascular history, abiraterone might not be a good choice for them. Or a patient with neuropathy, docetaxel might not be a good choice for them. But, within this guideline, it really will be up to date and focused on the busy clinician and knowing what the options are for their patient. Brittany Harvey: Definitely. This new era of living guidelines is very exciting and can provide even more up-to-date, evidence-based recommendations to really support clinicians and patients with metastatic castration-resistant prostate cancer. So in that vein, finally, what is the panel examining, and what are you excited for for new data coming out for future updates to this living guideline? Dr. Mary-Ellen Taplin: The future updates will depend on the results of phase III clinical trials. You know, there are many phase III trials ongoing in advanced prostate cancer, some of which include targeted therapy, which has been long awaited in prostate cancer. So such compounds as antibody-drug conjugates that are targeting certain proteins in prostate cancer cells, such as STEAP1, KLK2, B7-H3. So I think we are entering a new era in prostate cancer where we will be targeting cells and delivering drugs and applying them to prostate cancer if the trials are positive. So I think with AI and a large investment in prostate cancer clinical drug development, I think the treatment options for our patients will be rapidly evolving in a manner not previously seen. So the guidelines need to follow along with these developments. Brittany Harvey: Definitely. It sounds like an exciting time for research in metastatic castration-resistant prostate cancer. And we will await the result of those phase III trials to inform this guideline and lead to future updates. So I want to thank you so much for your work to rapidly and continuously update these guidelines and for your time today, Dr. Taplin. Dr. Mary-Ellen Taplin: Oh, it was my pleasure. ASCO has been a leader in this area, and as a practicing clinician, we are thankful for the investment and guidance that ASCO gives us. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App, available in the  Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Earlier this week, Trump was once again threatening to withhold funding from Chicago and other sanctuary cities with stated commitments to protecting immigrants. We sat down with TV host Brandon Pope and South Side Weekly's Alma Campos to discuss whether these threats will withstand ongoing legal challenges. Plus, Venezuelans migrants feel left in limbo, Fulton Market's business rents are skyrocketing, and the MSI's newest exhibits are a must-visit.  Want some more City Cast Chicago news? Then make sure to sign up for our Hey Chicago newsletter.  Follow us @citycastchicago You can also text us or leave a voicemail at: 773 780-0246 Learn more about the sponsors of this Jan. 16 episode:  Museum of Contemporary Photography Chicago Restaurant Week Broadway in Chicago Window Nation Become a member of City Cast Chicago. Interested in advertising with City Cast? Find more info HERE

Peggy Smedley and Brandon Michalski, chief economist, MSI, talk about two new reports that look at what is happening now and what is coming in the future. He says he looks at the noise versus the signal, and points to a few key areas as examples. They also discuss: · Tariffs and how it might impact the construction industry in 2026. · The surge in data center projects that will reshape infrastructure for years to come—and how retail factors in. · What will likely unfold in 2026 in construction—and how projects are being reshaped. https://mocasystems.com/

What if we told you that CES did not feature any new GPUs?  But it did feature more frames!  MSI with LIGHTNING and GPU safeguard, Phison's new controller, and that wily AMD with new Ryzen 7 9850X3D (and confirmed Ryzen 9 9950X3D2) - whee!  Remember the Reboot computer generated cartoon?  Remember D-Link Routers and Zero Days?  Remember Intel?  It's all here! That and everything old is new again with Old GPUs and CPUs coming back .. because RAM.Thanks again to our sponsor with CopilotMoney!  Get on your single pane of financial glass and bring order to your money and spending - it's even actually fun to save again.  Get the web version and use our code for 26% off at http://try.copilot.money/pcperTimestamps:0:00 Intro00:56 Patreon01:37 Food with Josh04:10 AMD announces Ryzen 7 9850X3D05:41 AMD sort of confirmed the 9950X3D207:00 NVIDIA DLSS 4.509:34 Intel was at CES12:50 MSI LIGHTNING returns14:54 MSI also launching GPU Safeguard Plus PSUs19:44 WD_Black is now Sandisk Optimus GX Pro21:54 Phison has the most efficient SSD controller26:11 ASUS ROG RGB Stripe OLED28:44 First computer-animated TV show restored33:29 Podcast sponsor - Copilot Money34:57 (In)Security Corner44:32 Gaming Quick Hits1:06:31 Picks of the Week1:24:08 Outro ★ Support this podcast on Patreon ★

Thanks to MSI for sponsoring this episode! Check out their MAG 272QP QD-OLED at https://lmg.gg/KS4hb Visit https://www.squarespace.com/WAN and use offer code WAN for 10% off Get an exclusive 15% discount on Saily data plans! Use code WANSHOW at checkout. Download Saily app or go to https://saily.com/wanshow Everything's giftable — Vessi Stormburst and Gloves are in stock & ready to wrap. Shop now: https://vessi.com/wanshow and get 15% off your first pair! • Free shipping • 30‑day returns • 1‑year warranty Get a Circuit Board skin for your device so dbrand can keep messing with Linus at https://dbrand.com/pcb Check out Dell's powerful business laptops at: https://lmg.gg/dellprowan Pick up a Secretlab Titan Evo Ergonomic Gaming Chair today at: https://lmg.gg/secretlabwan Get a special deal on Private Internet Access VPN today at https://www.piavpn.com/LinusWan Purchases made through some store links may provide some compensation to Linus Media Group. Learn more about your ad choices. Visit megaphone.fm/adchoices

Commercial real estate is hitting rock bottom. We will explain how to buy discounted distressed debt without owning a single office building.Today's Stocks & Topics: CF Industries Holdings, Inc. (CF), Market Wrap, Safe Route to Invest, Carrier Global Corporation (CARR), “CRE Distress: Where Are the Opportunities?”, IPOs, Waymo or Tesla, Axcelis Technologies, Inc. (ACLS), The Trade Desk, Inc. (TTD), Small Caps, Motorola Solutions, Inc. (MSI), Cash Holdings in Portfolios.Our Sponsors:* Check out ClickUp and use my code INVEST for a great deal: https://www.clickup.com* Check out Incogni: https://incogni.com/investtalk* Check out Invest529: https://www.invest529.com* Check out NordProtect: https://nordprotect.com/investalk* Check out Progressive: https://www.progressive.com* Check out Quince: https://quince.com/INVEST* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands